阿托伐他汀联合普罗布考对亚临床动脉粥样硬化患者的影响研究  

Effect of atorvastatin combined with probucol on the serum levels of SAA and MCP-1 in elderly patients with subclinical atherosclerosis

作　　者：胡武明[1] 况晓东[2] 徐剑[1] 叶士勇[1] 吴小燕[1] 林莉[1] 施振华[1] 陈志辉[1] 向贻佳[1] HU Wu-ming;KUANG Xiao-dong;XU Jian;YE Shi-yong;WU Xiao-yan;LIN Li;SHI Zhen-hua;CHEN Zhi-hui;XIANG Yi-jia(Department of Internal Medicine,The Central Hospital of Lishui,Lishui,Zhejiang 323000,China;不详)

机构地区：[1]丽水市中心医院心内科,浙江丽水323000 [2]南昌大学医学院病理教研室

出　　处：《中国预防医学杂志》2019年第10期988-991,共4页Chinese Preventive Medicine

摘　　要：目的探讨阿托伐他汀联合普罗布考对亚临床动脉粥样硬化老年患者血清中性粒细胞趋化蛋白-1(neutrophil chemotactic protein 1,MCP-1)与淀粉样蛋白A(serum amyloid A,SAA)的影响。方法选取2016年1月至2018年6月丽水市中心医院体检的亚临床动脉粥样硬化老年患者110例,按照随机数字表法分为观察组与对照组,观察组56例,对照组54例。对照组服用阿托伐他汀片,观察组在对照组基础上服用普罗布考片,两组患者均连续服用1年。比较两组患者治疗前后颈动脉内膜中层厚度(intima media thickness,IMT)值和血脂改变,检测血清SAA与MCP-1的表达水平。结果两组患者治疗后颈动脉IMT值差异有统计学意义(t=2.305,P=0.023)。两组TG、TC、LDL-C值下降,HDL-C值上升,差异比较有统计学意义(t=3.910、1.082、1.727、3.111,P=0.000、0.028、0.008、0.002)。两组患者SSA(t=2.268,P=0.026),MCP-1(t=2.881,P=0.005)差异有统计学意义。结论普罗布考能有效改善亚临床动脉粥样硬化患者粥样硬化程度,调节血脂,降低SAA与MCP-1的表达水平,不良反应小,安全性高。Objective To observe the effects of atorvastatin combined with probucol on serum levels of neutrophil chemotactic protein 1(MCP-1)and amyloid A(SAA)in elderly patients with subclinical atherosclerosis.Methods A total of 110elderly patients with subclinical atherosclerosis who underwent physical examination in The Central Hospital of Lishui from January 2016to June 2018were included and randomly divided into observation group(n=56)and control group(n=54).Subjects in control group were given torvastatin tablets,while those in the observation group were given probucol tablets as a plus for a year.The changes of IMT and blood lipids were compared between the two groups before and after treatment,and serum levels of SAA and MCP-1were detected.Results After treatment,the difference of IMT between the two groups was statistically significant(t=2.305,P=0.023).After treatment,the serum levels of TG,TC and LDL-C decreased,while the level of HDL-C increased in both groups,especially in the observation group,the differences between the two groups were statistically significant(t=3.910,1.082,1.727,3.111,P=0.000,0.028,0.008,0.002).After treatment,the levels of SSA and MCP-1decreased in both groups,which were significantly lower in observation group(t=2.268,2.881,P=0.026,0.005).Conclusions Probucol can effectively help to alleviate the atherosclerosis in patients with subclinical atherosclerosis by regulating blood lipids and reducing the expression of SAA and MCP-1,with low adverse reactions and high safety.

关 键 词：阿托伐他汀 普罗布考 亚临床动脉粥样硬化 淀粉样蛋白A 血清中性粒细胞趋化蛋白-1 

分 类 号：R743.3[医药卫生—神经病学与精神病学]